| |
Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19
Polymorphisms on the Pharmacokinetics of Etravirine.
Green B, Crauwels H, Kakuda TN,
et al
Clin Pharmacokinet. 2016 Sep 24
Abstract
Drug
susceptibility to etravirine and darunavir among Human Immunodeficiency Virus
Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in
South Korea.
Kwon OK, Kim SS, Rhee JE, et al
Virol J. 2015 Apr 9;12(1):53.
Paper
Decreased
phenotypic susceptibility to etravirine in patients with predicted genotypic
sensitivity.
Agneskog E, Nowak P, Maijgren Steffensson C, et al
PLoS One. 2014 Jul 7;9(7):e101508.
Paper
Etravirine in treatment-experienced, HIV-1-infected children and
adolescents: 48-week safety, efficacy and resistance analysis of the phase II
PIANO study.
Tudor-Williams G, Cahn
P, Chokephaibulkit K, et al
HIV Med.
2014 Mar 3.
Abstract
Influence of adding etravirine on complexity index and
patients' perceived complexity.
Calvo-Cidoncha E, González-Bueno J, Almeida-González CV, Morillo-Verdugo R.
J Clin Pharm Ther. 2013 Dec 23
Abstract
Patterns of Use and Outcomes in Patients Treated with
Etravirine in the HIV Research Network.
Gebo K, Voss C, Mrus J, HIV Research Network.
AIDS
Res Treat. 2013;2013:492831
Abstract |
Etravirine in CSF is highly protein bound.
Nguyen A, Rossi S, Croteau D, et al
J Antimicrob Chemother. 2013 Jan 20.
Abstract |
Etravirine concentrations
in seminal plasma in HIV-infected patients.
Tiraboschi J, Niubo J, Ferrer E,
et al
J Int AIDS Soc. 2012 Nov
11;15(6):18341.
Abstract
Etravirine Concentrations in the Cervico-Vaginal Compartment in
HIV-1 infected Women receiving Etravirine-containing antiretroviral therapy:
DIVA 02 study.
Clavel C, Peytavin G, Tubiana R,
et al
Antimicrob Agents Chemother.
2012 Apr 23.
Abstract
Etravirine concentrations in CSF in HIV-infected patients.
Tiraboschi JM, Niubo J, Vila A,
et al
J Antimicrob Chemother.
2012 Feb 22
Abstract |
Connection Domain Mutations in HIV-1 Reverse Transcriptase do not
Impact Etravirine Susceptibility and Virologic Responses to Etravirine-containing Regimens.
Gupta S, Vingerhoets J, Fransen S,
et
al.
Antimicrob Agents Chemother.
2011 Apr
Abstract
A randomized crossover study to compare efavirenz and
etravirine treatment.
Nguyen A, Calmy A, Delhumeau
C, et al
AIDS. 2010 Nov 11.
Abstract |
Etravirine in the Treatment of HIV-1: A Clinical
Overview for Healthcare Professionals.
Yeni P, Mills A, Peeters M, Vingerhoets J,
et al
Curr HIV Res.
2010 Oct 13.
Abstract |
Etravirine: clinical review of a treatment option for HIV type-1-infected
patients with
non-nucleoside reverse transcriptase inhibitor resistance.
Towner WJ, Cassetti I, Domingo P, et al
Antivir Ther. 2010;15(6):803-16.
Abstract
|
Physicochemical properties of the amorphous drug, cast films, and spray dried
powders
\to predict formulation probability of success for solid dispersions:
Etravirine.
Weuts I, Van Dycke F, Voorspoels J
J Pharm Sci.
2010 Jun 22
Abstract |
Crystal Structures of HIV-1 Reverse Transcriptase with Etravirine
(TMC125) and Rilpivirine (TMC278): Implications for Drug Design.
Lansdon EB, Brendza KM, Hung M, et al
J Med Chem.
2010 May 3
Abstract |
Profile of etravirine for the treatment of HIV infection.
Tseng A, Macarthur RD.
Ther Clin Risk Manag.
2010 Feb 2;6:49-58.
Abstract |
Etravirine: A novel nonnucleoside reverse transcriptase inhibitor for
managing human
immunodeficiency virus infection.
Elsayed RK, Caldwell DJ.
Am J Health Syst Pharm.
2010 Feb 1;67(3):193-205.
Abstract |
Factors associated with virological response to etravirine in
nonnucleoside reverse
transcriptase inhibitor-experienced HIV-1-infected patients.
Marcelin AG, Flandre P, Descamps D, et al
Antimicrob Agents Chemother.
2010 Jan;54(1):72-7
Abstract
|
New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics,
and resistance profile
of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.
Hughes CA, Robinson L, Tseng A, Macarthur RD.
Expert Opin Pharmacother. 2009
Aug 13.
Abstract |
Etravirine: new drug. Multidrug-resistant HIV: another option.
[No authors listed]
Prescrire Int.
2009 Jun;18(101):102-3.
Abstract |
Etravirine: A second-generation nonnucleoside reverse transcriptase
inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS, Youssef-Bessler M.
Clin Ther. 2009
Apr;31(4):692-704.
Abstract |
Etravirine, a Next-Generation Nonnucleoside Reverse-Transcriptase Inhibitor.
Johnson LB, Saravolatz LD.
Clin Infect Dis. 2009 Mar
10
Abstract
|
Is there a role for etravirine in patients with Nonnucleoside reverse
transcriptase inhibitor
resistance?
Scott C, Grover D, Nelson M.
AIDS. 2008 May 11;22(8):989-90.
Abstract
|
Etravirine.
Knoll BM, Vento S, Temesgen Z.
Drugs Today (Barc). 2008 Jan;44(1):23-33
Abstract |
FULL-TEXT ARTICLE
TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor
active against
nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency
virus type 1.
Andries K, Azijn H, Thielemans T, et al
Antimicrob Agents Chemother. 2004
Dec;48(12):4680-6.
Paper
|
|
| |
Pharmacokinetics of Total and Unbound Etravirine in
HIV-1-Infected Pregnant Women.
Ramgopal M, Osiyemi O, Zorrilla C,
et al
J Acquir Immune Defic Syndr.
2016 May 6.
Abstract
Comparison of population pharmacokinetics based on steady-state
assumption versus electronically monitored adherence to lopinavir, atazanavir,
efavirenz, and etravirine: A retrospective study.
Aline F, Aurélie R, Matthias C,
et al
Ther Drug Monit. 2016 Mar
1.
Abstract
Pharmacokinetics
of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse
Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected
Patients.
Orrell C, Felizarta F, Nell A, et al
AIDS Res Treat. 2015;2015:938628.
Paper
Single-dose pharmacokinetics of pediatric and adult formulations
of etravirine and swallowability of the 200-mg tablet: results from three Phase
1 studies.
Kakuda TN, Berckmans C, De Smedt G, et al
Int J Clin Pharmacol Ther.
2013 Aug 7
Abstract
Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once
Daily in Treatment-Naïve Patients.
Di Perri G, Green B, Morrish G, , et al
HIV Clin Trials. 2013
May-Jun;14(3):92-8.
Abstract
Steady-State Pharmacokinetics of Etravirine and
Lopinavir/Ritonavir Melt Extrusion Formulation, Alone and in Combination, in
Healthy HIV-Negative Volunteers.
Schöller-Gyüre M, Kakuda TN,
et al
J Clin Pharmacol. 2013 Feb;53(2):202-10
Abstract |
Pharmacokinetics of Maraviroc, Raltegravir, Darunavir, and
Etravirine in the Semen of HIV-Infected Men.
Antoniou T, Hasan S, Loutfy MR, et al
J Acquir Immune Defic Syndr. 2013 Feb
1;62(2):e58-60.
Abstract
Pharmacokinetics and Short-Term Safety of Etravirine in
Combination With Fluconazole or Voriconazole in HIV-Negative Volunteers.
Kakuda TN, Van Solingen-Ristea R, Aharchi F, et al
J Clin Pharmacol. 2013
Jan;53(1):41-50.|
Abstract |
Pharmacogenetics-based population pharmacokinetic analysis of
etravirine in HIV-1 infected individuals
Lubomirov R, Arab-Alameddine M, Rotger M,
et al
Pharmacogenet Genomics.
2012 Oct 29.
Abstract
Steady-State Pharmacokinetics of Etravirine and Lopinavir/Ritonavir Melt
Extrusion
Formulation, Alone and in Combination, in Healthy HIV-Negative Volunteers.
Schöller-Gyüre M, Kakuda TN,
et al
J Clin Pharmacol.
2012 May 1.
Abstract
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in
HIV-1-Infected, Treatment-Experienced
Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.
Kakuda T, Sekar V, Vis P, et al
AIDS Res Treat. 2012;2012:186987
Abstract |
FULL-TEXT ARTICLE
Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in
HIV-1–Infected, Treatment-Experienced Patients in the
Gender, Race, and Clinical Experience (GRACE) Trial
Kakuda T, Sekar V,
Vis P, et al
AIDS Research and Treatment Vol 2012 Art ID 186987|
Paoer
Pharmacokinetics and short-term safety and tolerability of
etravirine in treatment-experienced HIV-1-infected
children and adolescents.
Königs C, Feiterna-Sperling C, Esposito S, et al
AIDS. 2011 Dec 7
Abstract
Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily
versus 200 mg of etravirine twice daily in HIV-infected patients.
Gutiérrez-Valencia A, Martin-Peña R,
et al
J Antimicrob Chemother. 2011 Dec 21
Abstract
Darunavir, Ritonavir and Etravirine Pharmacokinetics in the
Cervicovaginal Fluid and Blood
Plasma of HIV-Infected Women
Patterson K, Jennings S, Falcon R, et al
Antimicrob Agents Chemother.
2010 Dec 20
Abstract |
Pharmacokinetic evaluation of etravirine.
Dickinson L, Khoo S, Back D.
Expert Opin Drug Metab Toxicol.
2010 Dec;6(12):1575-1585.
Abstract |
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in
treatment experienced
patients.
Barrail-Tran A, Yazdanpanah Y, Goldwirt L, et al
AIDS.
2010 Oct 23;24(16):2581-3.
Abstract |
Pharmacokinetics and Pharmacodynamics of the Non-Nucleoside
Reverse-Transcriptase
Inhibitor Etravirine in Treatment-Experienced HIV-1-Infected Patients.
Kakuda TN, Wade JR, Snoeck E,
et al
Clin Pharmacol Ther.
2010 Sep 29.
Abstract |
Pharmacokinetics of once-daily etravirine without and with once-daily
darunavir/ritonavir
in antiretroviral-naive HIV type-1-infected adults.
DeJesus E, Lalezari JP, Osiyemi OO,
et al
Antivir Ther. 2010;15(5):711-20.
Abstract |
Clinical pharmacokinetics and pharmacodynamics of
etravirine.
Schöller-Gyüre M, Kakuda TN, Raoof A,
et al
Clin Pharmacokinet.
2009;48(9):561-74
Abstract |
Pharmacokinetics and Safety of Etravirine Administered Once or Twice
Daily After 2 Weeks Treatment With Efavirenz in Healthy Volunteers.
Boffito M, Jackson A, Lamorde M, et al
J Acquir Immune Defic Syndr.
2009 Jul 17
Abstract |
Single- and multiple-dose pharmacokinetics of etravirine administered as two
different
formulations in HIV-1-infected
patients.
Kakuda TN, Schöller-Gyüre M,
Antivir Ther. 2008;13(5):655-61.
Abstract |
A pharmacokinetic study of etravirine (TMC125)
co-administered with ranitidine and omeprazole in
HIV-volunteers.
Schöller-Gyüre M, Kakuda TN, De Smedt G, et al
Br J Clin Pharmacol.
2008 May 19
Abstract |
Pharmacokinetic and Pharmacodynamic Study of the Concomitant
Administration of
Methadone and TMC125 in HIV-Negative Volunteers.
Schöller-Gyüre M, van den Brink W, et al
J Clin Pharmacol.
2008 Jan 14
Abstract |
| |
Prevalence in the USA of rilpivirine resistance-associated
mutations in clinical samples and effects on phenotypic susceptibility to
rilpivirine and etravirine.
Picchio GR, Rimsky LT, Van Eygen V, et al
Antivir Ther. 2014 Apr 4.
Abstract
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of
cellular HIV-1 DNA for the detection of drug resistance prior to starting
first-line antiretroviral therapy with etravirine or efavirenz.
Geretti AM, Conibear T, Hill A, et al
J Antimicrob Chemother. 2013
Nov 27
Abstract
The Connection Domain Mutation N348I in HIV-1 Reverse
Transcriptase Enhances Resistance to Etravirine and Rilpivirine but Restricts
the Emergence of the E138K Resistance Mutation by Diminishing Viral Replication
Capacity.
Xu HT, Colby-Germinario SP, Oliveira M, et al
J Virol. 2013 Nov 13.
Abstract
Genetic barrier to the development of resistance to rilpivirine
and etravirine between HIV-1 subtypes CRF02_AG and B.
Fofana DB, Soulie C, Maiga AI, et al
J Antimicrob Chemother. 2013 Jul 5.
Abstract
Increasing rate of TAMs and etravirine resistance in
HIV-1-infected adults between 12 and 24 months of treatment: The VOLTART cohort
study in Côte d'Ivoire, West Africa.
Messou E, Chaix ML, Gabillard D, et al
J Acquir Immune Defic Syndr. 2013
Jun 21
Abstract
Replication fitness of multiple NNRTI-resistant HIV-1 variants in
the presence of etravirine measured by 454 deep sequencing.
Brumme CJ, Huber KD,
Dong W, et al
J Virol. 2013 May 29
Abstract
The Effect of Mutations at Position E138 in HIV-1 Reverse
Transcriptase and their Interactions with the M184I Mutation in Defining
Patterns of Resistance to the Non-Nucleoside Reverse Transcriptase Inhibitors
Rilpivirine and Etravirine.
Xu HT, Colby-Germinario SP, Asahchop
EL, et al
Antimicrob Agents Chemother. 2013 Apr
22.
Abstract
Evaluation of etravirine resistance in clinical samples by a
simple phenotypic Test.
Agneskog E, Nowak P,
Källander CF, Sönnerborg A.
J Med Virol. 2013 Apr;85(4):703-8.
Abstract |
FULL-TEXT ARTICLE
Virological
outcome and patterns of HIV-1 drug resistance in patients with 36 months'
antiretroviral therapy experience in Cameroon.
Aghokeng AF, Kouanfack C, Eymard-Duvernay S,
et al
J Int AIDS Soc. 2013 Jan
31;16:18004.
Paper |
Distinct resistance patterns to etravirine and rilpivirine in
viruses containing nnrti mutations at baseline.
Asahchop EL, Wainberg MA, Oliveira M,
et al
AIDS. 2012 Dec 19.
Abstract
Genotypic susceptibility to etravirine-assessment in a population of
NNRTI-experienced patients.
Piñeiro C, Xerinda S, Figueiredo C, et al
J Int AIDS Soc.
2012 Nov 11;
Abstract
FULL-TEXT ARTICLE
Panel of
prototypical recombinant infectious molecular clones resistant to nevirapine,
efavirenz, etravirine, and rilpivirine.
Balamane M, Varghese V, Melikian GL,
et al
Antimicrob Agents Chemother.
2012 Aug;56(8):4522-4
Paper |
Susceptibility to Etravirine of HIV-1 subtype C isolates from
Nevirapine/Efavirenz-experienced patients: comparative
interpretation of ANRS and STANFORD algorithms.
Fleury HJ, Anquetil D, Deshpande A,
et al
AIDS Res Hum Retroviruses.
2012 Apr 20.
Abstract
Prevalence of etravirine resistance associated mutations in HIV-1 strains
isolated from infected individuals
failing efavirenz: comparison between subtype B and non-B genetic variants.
Pereira-Vaz J, Duque V, Pereira B,
et al
J Med Virol. 2012 Apr;84(4):551-4.
Abstract
Prevalence of etravirine resistance associated mutations in HIV-1
strains isolated from infected
individuals failing efavirenz: Comparison between subtype B and non-B
genetic variants.
Pereira-Vaz J, Duque V, Pereira B,
et al
J Med
Virol. 2012 Apr;84(4):551
Abstract |
Emerging mutations and associated factors in patients displaying
treatment failure on an
etravirine-containing regimen.
Marcelin AG, Descamps D, Tamalet C, et al
Antivir Ther.
2012;17(1):119-123.
Abstract |
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults
failing non-nucleoside
reverse transcriptase inhibitor-based regimens.
Bunupuradah T, Ananworanich J, Chetchotisakd P,
et al
Antivir Ther. 2011;16(7):1113-21
Abstract |
Interaction of reverse transcriptase (RT) mutations conferring resistance to
lamivudine and etravirine:
effects on fitness and RT activity of human immunodeficiency virus type 1.
Hu Z, Kuritzkes DR.
J Virol.
2011 Aug 17.
Abstract
Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on
Phenotypic Susceptibility
and Virologic Response to Etravirine.
Tambuyzer L, Nijs S, Daems B,
Picchio G, Vingerhoets J.
J Acquir Immune Defic Syndr.
2011 Jun 2
Abstract
Prevalence of Susceptibility to Etravirine by Genotype and Phenotype in Samples
Received for
Routine HIV-1 Resistance Testing in the USA.
Picchio G, Vingerhoets J, Tambuyzer L,
et al
AIDS Res Hum Retroviruses. 2011
May 10
Abstract
Predicted susceptibility of etravirine in HIV patients experiencing
virological failure
secondary to non-nucleoside reverse transcriptase inhibitor resistance
in Argentina.
Córdova E, Loiza E, Porteiro N, Mingrone H.
Enferm Infecc Microbiol Clin.
2011 May 16.
Abstract
Resistance analyses in highly experienced patients failing
raltegravir, etravirine
and darunavir/ritonavir regimen.
Charpentier C, Roquebert B, Colin C, et al
AIDS. 2010 Aug 26
Abstract |
Prevalence of mutations and determinants of genotypic resistance to
etravirine (TMC125) in a large Italian resistance database (ARCA)dagger.
Di Vincenzo P, Rusconi S, Adorni F, et al
HIV Med.
2010 Mar 8
Abstract |
Etravirine limits the emergence of darunavir and other protease inhibitor
resistance-associated
mutations in the DUET trials.
Peeters M, Vingerhoets J, Tambuyzer L,
et al
AIDS. 2010 Feb 12.
Abstract.|
Resistance profile of etravirine: combined analysis of baseline
genotypic and phenotypic data from the randomized, controlled Phase III clinical
studies.
Vingerhoets J, Tambuyzer L, Azijn H, et al
AIDS 2010
Jan 5.
Abstract.
Prevalence of etravirine mutations and impact on response to treatment
in routine clinical care:
the Swiss HIV Cohort Study (SHCS).
Scherrer AU, Hasse B, von Wyl V, et al
HIV Med. 2009 Sep 1
Abstract
HIV-1 recombinant reverse transcriptase enzymes containing the G190A
and
Y181C resistance mutations remain sensitive to etravirine.
Xu H, Quan Y, Brenner BG, Bar-Magen T, et al
Antimicrob Agents Chemother.
2009 Aug 24
Abstract
Additional HIV-1 mutation patterns associated with reduced
phenotypic susceptibility to etravirine
in clinical samples.
Kagan RM, Sista P, Pattery T, et al
AIDS. 2009 May
25
Abstract
Prediction of the virological response to etravirine
in clinical practice: Comparison of three genotype algorithms.
Cotte L, Trabaud MA, Tardy JC,
et al
J Med Virol.
2009 Feb 23;81(4):672-677
Abstract
Prevalence of etravirine-associated mutations in clinical samples
with resistance to nevirapine and efavirenz.
Llibre JM, Santos JR, Puig T, et al
J Antimicrob Chemother. 2008 Jul 23.
Abstract |
|
|
Etravirine
Main Page
Main
New/Newsworthy
Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
